689 related articles for article (PubMed ID: 33174058)
1. Triple‑negative breast cancer therapy: Current and future perspectives (Review).
Won KA; Spruck C
Int J Oncol; 2020 Dec; 57(6):1245-1261. PubMed ID: 33174058
[TBL] [Abstract][Full Text] [Related]
2. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
Li CJ; Lin LT; Hou MF; Chu PY
Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
[TBL] [Abstract][Full Text] [Related]
3. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
Gupta T; Vinayak S; Telli M
Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
[TBL] [Abstract][Full Text] [Related]
5. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.
Segovia-Mendoza M; Romero-Garcia S; Lemini C; Prado-Garcia H
J Immunol Res; 2021; 2021():6668573. PubMed ID: 33506060
[TBL] [Abstract][Full Text] [Related]
6. Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.
Chen Z; Wang X; Li X; Zhou Y; Chen K
J Int Med Res; 2021 Feb; 49(2):300060521991019. PubMed ID: 33541181
[TBL] [Abstract][Full Text] [Related]
7. Biology and Management of Patients With Triple-Negative Breast Cancer.
Sharma P
Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
[TBL] [Abstract][Full Text] [Related]
8. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
Tazzite A; Jouhadi H; Benider A; Nadifi S
Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
[TBL] [Abstract][Full Text] [Related]
9. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
[TBL] [Abstract][Full Text] [Related]
10. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
11. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
12. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
13. p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy.
Coradini D; Biganzoli E; Ardoino I; Ambrogi F; Boracchi P; Demicheli R; Daidone MG; Moliterni A
Breast; 2015 Jun; 24(3):294-7. PubMed ID: 25698149
[TBL] [Abstract][Full Text] [Related]
14. Metaplastic breast cancer: an old histotype but a current therapeutic problem.
Gadaleta-Caldarola G; Nenna R; Lanotte L; Doronzo A; Gadaleta-Caldarola A; Roma I; Lombardi L; Infusino S
Future Oncol; 2021 Mar; 17(8):955-963. PubMed ID: 33538176
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
16. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.
Qin G; Wang X; Ye S; Li Y; Chen M; Wang S; Qin T; Zhang C; Li Y; Long Q; Hu H; Shi D; Li J; Zhang K; Zhai Q; Tang Y; Kang T; Lan P; Xie F; Lu J; Deng W
Nat Commun; 2020 Apr; 11(1):1669. PubMed ID: 32245950
[TBL] [Abstract][Full Text] [Related]
17. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
[No Abstract] [Full Text] [Related]
18. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S
Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904
[TBL] [Abstract][Full Text] [Related]
19. Quadruple-negative breast cancer: novel implications for a new disease.
Bhattarai S; Saini G; Gogineni K; Aneja R
Breast Cancer Res; 2020 Nov; 22(1):127. PubMed ID: 33213491
[TBL] [Abstract][Full Text] [Related]
20. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
